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Pro- and antiinflammatory cytokines
in threatened miscarriages
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w
rOBJECTIVE: The purpose of this study was to evaluate circulating and
intracellular levels of Th1 and Th2 cytokines in women with threatened
miscarriage (TM) and subsequent outcome.
STUDY DESIGN: Plasma levels of tumor necrosis factor (TNF)-recep-
ors 1 and 2, TNF, interferon gamma (IFN), and interleukins (IL) -6
and -10 were measured by flow cytometric bead assays in 80 women
with TM: 53 women with normal outcome and 27 women who miscar-
ried. Fluorescent antibody labeling was also performed on whole blood
in a subgroup of 27 women of TM: 16 women with normal outcome and2011;205:83.e8-16.
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83.e8 American Journal of Obstetrics& Gynecology JULY 2011RESULTS: Monocyte expression of TNF and circulating levels of
NF, IFN, IL-10, IL-6, and TNF-R1 were significantly lower, whereas
circulating levels of TNF/IL-10, IFN/IL-10, and TNF/IL-6 ratios
ere significantly higher, in women with TM who subsequently miscar-
ied, compared with the women with normal outcome.
CONCLUSION: An increased Th1 type of immune response, which was
similar to that observed in preterm delivery, was found in TM cases that
were complicated by a subsequent miscarriage.
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Cite this article as: Calleja-Agius J, Muttukrishna S, Pizzey AR, et al. Pro- and antiinflammatory cytokines in threatened miscarriages. Am J Obstet GynecolThreatened miscarriage (TM) is de-fined as a history of vaginal bleeding
n early pregnancy in the presence of a
losed cervix and with ultrasonic evi-
ence of an intrauterine gestational sac
nd a fetal heartbeat.1 TM is the most
ommon complication of ongoing preg-
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© 2011 Published by Mosby, Inc.ancy, which occurs in approximately
0% of pregnant women, and is associ-
ted with a 10-14% risk of full miscar-
iage.2,3 Various management protocols
have been developed that included con-
servative management and hormonal
therapy that were based on progester-
one4 and human chorionic gonadotro-
pin (hCG).5 Overall, TM can generate
great anxiety in patients, especially be-
cause bleeding in early pregnancy can
lead to pregnancy loss and other obstet-
ric complications.6
The pathophysiology of TM is linked
to bleeding from uteroplacental vessels
at the margin of the placenta with
blood accumulating between the cho-
rionic membrane and uterine wall.7
The formation of a subchorionic he-
matomamay disrupt the placental bed.
If the hematoma expands to the rest of
the placental mass, it will induce com-
plete miscarriage within a week of the
first symptoms.8 If bleeding is limited
or happens close to the internal cervi-
cal os and is evacuated, the pregnancy
may continue; however, this can lead
to a chronic inflammatory reaction
within the decidua and membranes.7,8
Within this context, TM is associated
with a higher incidence of preterm la-e of membranes,placental abruption, fetal growth re-
striction, and low birthweight.2,9-18
A strong association exists between
maternal T helper-1 (Th1)-type immu-
nity and pregnancy loss, whereas a shift
towards Th2-type cytokine response has
been observed in successful pregnancy.19
Cytokines are known to play an impor-
tant role in implantation. An imbalance
in cytokine production occurs in early
pregnancy loss.20-22 Cytokine receptors
such as tumor necrosis factor-receptor 1
(TNF-R1) have also been associatedwith
miscarriage in their role as apoptosis-
mediators through proinflammatory cy-
tokines such as tumor necrosis factor al-
pha (TNF).23
Several factors in the maternal his-
tory (such as age and smoking, bio-
markers that include serum hormones
levels, and the presence of a retropla-
cental hematoma on ultrasound scan-
ning) have been investigated as possi-
ble predictors of pregnancy outcome
in women with TM.24-27 It has been
shown that after TM, maternal serum
inhibin A in combination with other
serum markers, such as hCG, are
altered in women who subsequently
have a first-trimester miscarriage.28,29
The biomarkers that give the best pre-
dictive values are a combination of se-
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sensitivity of 88.1% and specificity of
84.3%.30 However, no biomarker of in-
ammation in the peripheral maternal
lood has been validated sufficiently to be
f any clinical use in counseling women
ith TM regarding their risks of subse-
uent miscarriage and other complica-
ions or for providing advice about the
enefit of specific treatment to reduce
hese risks.31 Recent data have indicated
hat treatment that corrects Th1/Th2 im-
alance, such as dydrogesterone, could
elp prevent TM from resulting in a full
iscarriage.32-35
TABLE 1
The limit of detection, intra- and in
of variation for each cytometric be
Cytokine/receptor
Assay
detect
pg/mL
Tumor necrosis factor– 0.7
...................................................................................................................
Interferon  1.8
...................................................................................................................
Interleukin-10 0.13
...................................................................................................................
Interleukin-6 1.6
...................................................................................................................
Tumor necrosis factor–receptor 1 5.2
...................................................................................................................
Tumor necrosis factor–receptor 2 1.4
...................................................................................................................
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TABLE 2
Fluorochromes used for dual antib
Patient
code
Monocyte
label Cytokine/
a CD-14: APC TNF rece
...................................................................................................................
b CD-14: APC TNF rece
...................................................................................................................
c CD-14: APC IgG1: PE
...................................................................................................................
d CD-14: APC IgG2: PE
...................................................................................................................
e CD-14: APC TNF: FIT
...................................................................................................................
f CD-14: APC TNF: FIT
...................................................................................................................
g CD-14: PE IFN: APC
...................................................................................................................
h CD-14: PE IFN: APC
...................................................................................................................
i CD-14: PE IL-10: PE
...................................................................................................................
j CD-14: PE IL-10: PE
...................................................................................................................
k CD-14: PE IL-6: biotin
...................................................................................................................
l CD-14: PE IL-6: biotin
...................................................................................................................
APC, allophycocyanin; FITC, fluorescein isothiocyanate; Ig, im
necrosis factor.Calleja-Agius. Cytokines and threatenedmiscarriage. Am J ObThe objective of this study was to
evaluate the changes in circulating lev-
els and intracellular expression of Th1
and Th2 cytokines in patients with TM
and to investigate whether these cyto-
kines are altered in patients who sub-
sequently miscarry. TNF and its re-
ceptors TNF-R1 and TNF-R2 and
interferon gamma (IFN) were mea-
sured to evaluate the Th1 cytokine re-
sponse, whereas interleukins (IL)-6
and -10 were measured to evaluate Th2
cytokine response. IL-6 was classified
as a Th2 cytokine because of its role in
early pregnancy.36 The role of these cy-
assay coefficients
assay
it of
,
Intraassay
coefficient of
variation, %
Interassay
coefficient of
variation, %
10.2 5.0
..................................................................................................................
10.8 5.0
..................................................................................................................
6.4 11.0
..................................................................................................................
9.4 8.0
..................................................................................................................
2.6 10.1
..................................................................................................................
7.1 5.6
..................................................................................................................
stet Gynecol 2011.
labeling of whole blood
eptor label
Lipopolysaccharide,
ng/mL
r I: PE —
..................................................................................................................
r II: PE —
..................................................................................................................
—
..................................................................................................................
—
..................................................................................................................
40
..................................................................................................................
—
..................................................................................................................
40
..................................................................................................................
—
..................................................................................................................
40
..................................................................................................................
—
..................................................................................................................
streptavidin PE 40
..................................................................................................................
streptavidin PE —
..................................................................................................................
oglobulin; IL, interleukin; PE, phycoerythrin; TNF, tumorstet Gynecol 2011.
JULY 2011 Ameriokines in predicting miscarriage was
lso investigated.
MATERIALS AND METHODS
Subjects and samples
A group of 80 women with first-trimes-
ter TM were recruited prospectively
from the Early Pregnancy Unit at Uni-
versity College London Hospital after
clinical diagnosis of TM (ie,12weeks 6
days of gestation as calculated from the
first day of their last menstrual period)
with vaginal bleeding and after an ultra-
sound confirmation of a singleton viable
pregnancy. Exclusion criteria included
patients with a history of recurrent
miscarriage, presence of twin preg-
nancy, hydatiform mole or a congeni-
tal uterine anomaly, presence of large
leiomyomata that was distorting the
uterine cavity, known history of cervi-
cal incompetence, thrombophilia, or
any medical condition that needed
chronic drug therapy.
Afterwritten informed consent, 10mL
of venous blood were collected by sterile
venipuncture. One milliliter of blood
was analyzed as part of a prospective
study that involved flow cytometric
analysis of fluorescent antibody-labeled
whole blood. This analysis had to be car-
ried out on fresh whole blood, without
prior knowledge of the outcome of the
index pregnancy. The remaining 9mL of
bloodwere centrifugedwithin 2 hours of
collection, and the plasma supernatant
was stored at20°C until it was assayed.
Measurement of cytokines/receptors in
plasma was done with knowledge of the
outcome of the index pregnancy (ie, as a
retrospective nested case control study).
A normal pregnancy outcomewas defined
as a singleton live birth at term and of
normal weight (3 kg). A miscarriage
was defined as pregnancy ending spon-
taneously at24 weeks of gestation. The
study was approved by University Col-
lege LondonHospital Committee on the
Ethics of Human Research.
Bioassays
Multiplex bead assays. TNF-receptors 1
and 2, TNF, interferon gamma (IFN),
IL-6, and IL-10 were assayed inmaternal
plasma using Cytometric Bead Arrayter
ad
lim
ion
.........
.........
.........
.........
.........
.........ody
rec
pto
.........
pto
.........
.........
.........
C
.........
C
.........
.........
.........
.........
.........

.........

.........
munHuman Soluble Protein Flex Sets (BD
can Journal of Obstetrics& Gynecology 83.e9
w
c
e
g
F
T
t
o
F
a
w
t
L
g
l
s
r
D
w
j
c
A
a
f
c
a
t
t
1
v
o
s
m
p
w
s
w
a
3
m
u
q
t
p
t
a
C
p
m
P
(
U
u
1
t
i
c
i
w
p
C
G
t
T
f
t
o
T
C
O
JOb
Research Basic Science: Obstetrics www.AJOG.orgBiosciences, San Jose, CA). The scope of
this cytometric bead array was to allow
for multiplexed analysis of different cy-
tokines and receptors on smaller quanti-
ties of plasma, when compared with the
use of conventional enzyme-linked im-
munosorbent assay. The experiment was
carriedout according to themanufactur-
er’s instructions and as previously pub-
lished.37 Acquisition of the sample data
as performed with a bioanalyzer flow
ytometer (BD FACSArray; BD Biosci-
nces). The data were presented in
raphic and tabular formats with the
CAP Array software (BD Biosciences).
he limit of detection for each assay and
he intraassay and interassay coefficients
f variation are shown in Table 1.
low cytometric analysis of fluorescent
ntibody-labeled whole blood. Initial
hole blood validation experiments showed
hat 40 ng/mL of lipopolysaccharide (40
PS) and an incubationperiodof 12hours
ave the highest increment above basal
evel (0 LPS) in terms of cytokine expres-
ion by the activated monocytes, while
etaining a high monocyte population.
ual antibody labeling was carried out
ith specific antibodies that were con-
ugated to spectrally distinct fluoro-
hromes to enable easy discrimination.
ll samples were labeled with mouse
nti-human antibody (AbDSerotec,Ox-
ord, UK) that was specific for mono-
ytes (CD 14). Different aliquots were
lso labeled with antihuman antibodies
hat were specific to the cytokine/recep-
or of interest (Table 2).
With the use of aseptic techniques,
.5 mL of whole blood from each indi-
idual patient was mixed with 1.5 mL
f Dulbecco phosphate-buffered saline
olution without Ca, Mg. One
illiliter of this whole blood/Dulbecco
hosphate-buffered saline solution
as placed into 4 200-L aliquots (Ta-
ble 2). The other 2 mL aliquots were
separated into 2 separate 1-mL ali-
quots. Ten microliters of monensin
sodium solution (Sigma-Aldrich, St.
Louis, MO) and 10 L of 40 LPS solu-
tion were added to 1 aliquot (stimu-
lated); only 10L of monensin sodium
olution (Sigma-Aldrich) without LPS
as added to the other aliquot. Both 4
83.e10 American Journal of Obstetrics& Gynecololiquots were placed in a water bath at
7°C and shaken at 20 rev/min. Nor-
al atmospheric composition was
sed instead of a CO2 system to ensure
that the samples were kept as close to
the physiologic state as possible. After
12 hours incubation, the samples in
each tube were further divided into 4
200-L aliquots, to a total of 8 ali-
uots, each of which was labeled with
he patient’s code and lettered e-l, de-
ending on the antibody combination
o be added and whether LPS was
dded (Table 2). Ten microliters of
D14 antibody were added to the sam-
le and incubated in the dark for 15
inutes at room temperature. Fix and
erm Cell Permeabilization Reagents
Caltag; Invitrogen, Paisley, Scotland,
K) were added according to the man-
facturer’s instructions, followed by 5
L of the second antibody (TNF, IL-
0, TNF receptor, or negative con-
rol). The sample was again incubated
n the dark for 20minutes, washed, and
entrifuged. The pellet was resuspended
n 200 L of wash buffer. Each cryovial
as kept at 4°C in the dark until the sam-
lewas read by the flowcytometer (Dako
yAn ADP; Advanced Digital Processing,
lostrup, Denmark), which was operated
hrough the Summit software (version
TABLE 3
Patient demographics
Parameter Outcome
Body mass index, kg/m2 Normal outco
................................
Miscarriage
...................................................................................................................
Gestation, wk Normal outco
................................
Miscarriage
...................................................................................................................
Parity, births Normal outco
................................
Miscarriage
...................................................................................................................
Age, y Normal outco
................................
Miscarriage
...................................................................................................................
White ethnicity, % Normal outco
................................
Miscarriage
...................................................................................................................
Patient demographics of all the patients with threatened mi
pregnancy outcome, 53 women; TM with subsequent miscarri
2 groups in terms of body mass index, gestation, parity, age,
a Considered to be not significant.
Calleja-Agius. Cytokines and threatenedmiscarriage. Am.31; Summit Software, Little Rock, AR).
gy JULY 2011he results were then saved in file format
or post-acquisition spectral compensa-
ion and data analysis (FCS 2.0; DakoCol-
rado Inc, Fort Collins, CO).
Statistical analysis
The results generated by the FCAP
Array software and Summit software
were entered in Microsoft Excel (ver-
sion 2003; Microsoft Corporation,
FIGURE 1
Comparison of cytokine
levels in plasma
TNF IFN IL-10 IL-6
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Graph shows significantly higher cytokine levels
in patients with threatened miscarriage (TM )
with normal outcome. See Table 4 for probability
values.
IL, interleukin; IFN, interferon; pg/mL, picograms per milliliter;
NF, tumor necrosis factor.
alleja-Agius. Cytokines and threatenedmiscarriage. Am J
bstet Gynecol 2011.
Mean SEM P valuea
23.63 .47 .63
.................................................................................................................
24.18 1.05
..................................................................................................................
8.10 .40 .24
.................................................................................................................
7.45 .37
..................................................................................................................
.43 .10 .61
.................................................................................................................
.52 .14
..................................................................................................................
30.57 .74 .07
.................................................................................................................
32.41 .68
..................................................................................................................
77 .59
.................................................................................................................
70
..................................................................................................................
iage (TM) who were recruited in this study (TM normal
27 women) showed no significant difference between the
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analysis, patients were matched for eth-
nicity, gestation, body mass index, age,
and parity. Data were normalized by log
FIGURE 2
Comparison of tumor necrosis fact
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FIGURE 3
Comparison of Th1/Th2 cytokine
ratios in plasma
There are significantly higher tumor necrosis factor
(TNF )-/IL-10, TNF-/interleukin (IL)-6, and inter-
feron (IFN )/IL-10 ratios in patients with threatened
miscarriage (TM ) who subsequently miscarried than
in women with a normal pregnancy outcome (P 
.001, P .049, P .001, respectively).
Calleja-Agius. Cytokines and threatenedmiscarriage. Am J
Obstet Gynecol 2011.transformation, and unpaired t test was
carried out for the plasma and intracel-
lular cytokine and receptor levels. The
mean and SEM of the actual values were
entered inGraphPadPrism5 (GraphPad
Software Inc, La Jolla, CA) to generate
graphs. Analysis was carried out with
SPSS software (version 12 for Windows;
SPSS Inc, Chicago, IL) for significance
testing. A probability value of .05 was
considered statistically significant.
Intercooled STATA 9.1 (StataCorp,
College Station, TX) was used to gener-
ate nonparametric receiver operator
characteristics curves for each cytokine/
receptor. Each biomarkerwas ranked ac-
cording to the area under the graph, and
confidence intervals were calculated. To
identify the best biomarker combination
for the prediction of miscarriage, step-
wise logistic regression was carried out,
followed by discriminant analysis on the
resulting combination to quantify the
specificity, sensitivity, and positive pre-
dictive value.38
RESULTS
Of the 80 patients with TMwho were re-
cruited in the retrospective nested case
control study, 53 patients had normal
pregnancy outcome that resulted in a
(TNF ) receptors in plasma
TNF-R2 in pg/mL
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atients with threatened miscarriage (TM ) with
t Gynecol 2011.singleton live birth at termandof normal
JULY 2011 Americweight (10-90th percentile); 27 patients
subsequentlymiscarried at24weeks of
estation. There was no statistical differ-
nce in bodymass index, parity, age, and
thnicity between patients with TMwith
ormal outcome and those who miscar-
ied (Table 3). The mean gestational age
or patients with TM who had normal
regnancy outcome and those who sub-
equently miscarried was not signifi-
antly different (9 weeks 6 days and 8
eeks 3 days, respectively;P .73). Flow
cytometric analysis of fluorescent anti-
body-labeled whole blood was carried
out on a subgroup of 27 patients: 16 pa-
tients had normal outcome, and 11 pa-
tients subsequently miscarried.
Circulating cytokine and receptor
levels in the plasma
Circulating levels of TNF, IFN, IL-10,
IL-6, and TNF-R1 in plasma were signif-
icantly higher in patients with TM who
had normal pregnancy outcome than in
patients who subsequently miscarried
(P .001, .05, .001, .005, and
05, respectively). TNF/IL-10, TNF/
L-6, and IFN/IL-10 ratios were signif-
cantly higher in patients with TM who
ubsequently miscarried than in those
ith normal pregnancy outcome (P 
001, .05, and .001, respectively; Fig-
res 1-3; Table 4).
The biomarker that was the best pre-
ictor of miscarriage was TNF-R2, with
he highest area under the curve (0.65;
5% confidence interval, 0.47–0.75; Ta-
le 5; Figure 4). At a cutoff value of 2202
g/mL, TNF-R2 gave a positive predic-
ive value of 44%, a sensitivity of 63%,
nd a specificity of 62%. Discriminant
nalysis showed that the best combina-
ion of biomarkers was TNF-R2 and
NF, which gave a positive predictive
value of 66%, a sensitivity of 54%, and a
specificity of 92%.
Intracellular cytokine and receptor
levels in whole blood
In whole blood, the number of CD-14
cells that were positive for each indi-
vidual cytokine was measured both at
unstimulated basal level (0 LPS) and
after LPS stimulation (40 LPS; Figure
4). In monocytes, there was a signifi-or
1
2
3
4
in p
bstecantly higher level of stimulated TNF
an Journal of Obstetrics& Gynecology 83.e11
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Research Basic Science: Obstetrics www.AJOG.orglevels (TNF 40 LPS/TNF 0 LPS; P 
.05) in women with TM who had nor-
mal pregnancy outcome compared
with those who miscarried. The me-
dian number of CD-14 cells that were
positive for TNF-Rs were measured at
unstimulated basal levels only, and
there was no significant difference be-
tween women with TM who had nor-
mal pregnancy outcome and those who
miscarried (Figure 5).
The ratio of Th1/Th2 cytokines was
calculated both at unstimulated basal
level and as a ratio of percentage fold in-
crease in cytokine expression. At basal
level, Th1/Th2 ratio was measured in
whole blood without LPS stimulation as
TNF/IL-10, TNF/IL-6, IFN/IL-10,
nd IFN/IL-6. Also, the percentage fold
ncreasewith LPS stimulation (40/0 LPS)
f each individual Th1 cytokine over
ercentage fold increase of each individ-
al Th2 cytokine was calculated. There
as no significant difference in any of the
TABLE 4
Comparison of circulating
cytokine and receptor levels
in the plasma in threatened
miscarriage with normal
pregnancy outcome and
with subsequent miscarriage
Cytokine/receptor P value
TNF  .001a
...........................................................................................................
IFN  .05a
...........................................................................................................
IL-10  .001a
...........................................................................................................
IL-6  .005a
...........................................................................................................
TNF-R1  .05a
...........................................................................................................
TNF-R2 Not significant
...........................................................................................................
TNF/IL-10  .001a
...........................................................................................................
TNF/IL-6  .05a
...........................................................................................................
IFN/IL-10  .001a
...........................................................................................................
IFN/IL-6 Not significant
...........................................................................................................
t test showed that there were statistically significant
elevated levels of TNF, IFN, IL-10, IL-6, and TNF-R1
in threatened miscarriage in women who proceeded to
live birth; the women with threatened miscarriage who
miscarried had statistically higher ratios of TNF/IL-
10, TNF/IL-6, and IFN/IL-10.
IFN, interferon; IL, interleukin; TNF, tumor necrosis fac-
tor.
a Considered to be statistically significant.
Calleja-Agius. Cytokines and threatenedmiscarriage.
Am J Obstet Gynecol 2011.atios between patients with TM with
83.e12 American Journal of Obstetrics& Gynecoloormal pregnancy outcome and those
ho miscarried (Figure 6).
COMMENT
The results of this study indicated that
women with TM during the first trimes-
ter who subsequently miscarried had an
imbalance in the circulatory Th1/Th2
cytokine levels, with a shift towards a
Th1 type of immune response. Similar
findings have been found previously in
women with recurrent or complete mis-
carriage,21,22 whereaswomenwith a nor-
al pregnancy outcome do not have an
mbalance in their plasma Th1/Th2 cy-
okine ratio.19,39,40 These findings sug-
gest that changes in levels of cytokines
could play a role in the determination of
the risk of miscarriage in women with
first trimester TM.
Themechanism by which intrauterine
bleeding alters maternal circulating hor-
mone and cytokine levels is not well-de-
fined. Up to week 9-10 of gestation, pla-
cental villi cover the entire surface of the
chorionic sac. As the gestational sac
grows during fetal life, the villi that are
associated with the decidua capsularis
surrounding the amniotic sac degenerate
and form the chorion leave, whereas villi
that are associated with the decidua
basalis proliferate and form the defini-
tive placenta.7 We previously have
hown that the underlying uteroplacen-
al circulation in the center of the prim-
tive placenta is plugged, whereas in pe-
iphery the mouth of the spiral arteries
re never plugged by the trophoblastic
hell, which allows limited maternal
lood flow to enter the marginal zone of
lacenta from 8-9 weeks of gestation.8
This leads to higher local O2 concentra-
tion at a stage of pregnancywhen the tro-
phoblast possesses low concentrations of
the main antioxidant enzymes superox-
ide dismutase, catalase, and glutathione
peroxidase.7 Focal trophoblastic oxi-
dative damage and progressive villous
degeneration trigger the formation of fe-
tal membranes, which remodels the
uteroplacental interface. First-trimester
vaginal bleeding has been associated
with increased maternal levels of free se-
rum -hCG,41 possibly because of a rise
in hCG transfer into the maternal circu-
gy JULY 2011lation because of the disruption of the
maternofetal interface. Bleeding in the
subchorionic space can result in elevated
bioavailability of free iron, catalyzing the
generation of hydroxyl radicals and sub-
sequent free-radical damage to the sur-
rounding tissues. The oxidative stress
and focal rise in oxygenation may also
stimulate the synthesis of various tro-
phoblastic proteins such as hCG and
estrogens.
We found that all cytokines that were
investigated in our study, both proin-
flammatory (TNF and IFN) and anti-
nflammatory (IL-10 and IL-6) and
NF-R1, were significantly higher in the
irculation of women with TM who had
normal pregnancy outcome than in
hose women who subsequently miscar-
ied. Intracellular TNF levels after LPS
timulation were also higher in TM with
normal pregnancy outcome. This is
omparable with the findings of another
tudy that shows that TNF production
n women with a history of recurrent
iscarriage who subsequently miscarry
s significantly lower than in normal
regnant women with successful out-
ome.42 It has been proposed that TNF
is essential in preventing the birth of off-
spring with structural anomalies43 and
rotects embryos who are exposed to de-
elopmental toxins.44 Therefore, the rise
n TNF and other cytokines could be
TABLE 5
Values of AUC of the ROC
curves and CIs for each
cytokine and receptor
Biomarker
Area under
the curve 95% CI
TNF-R2 0.65 0.47–0.75
...........................................................................................................
TNF-R1 0.36 0.22–0.50
...........................................................................................................
IFN 0.36 0.22–0.49
...........................................................................................................
IL-6 0.31 0.18–0.43
...........................................................................................................
TNF 0.29 0.19–0.39
...........................................................................................................
IL-10 0.12 0.01–0.23
...........................................................................................................
TNF-R2 is the best single predictor of miscarriage, with
an area under the curve of 0.65.
AUC, area under the curve; CI, confidence interval; IFN,
interferon; IL, interleukin; ROC, receiver operator char-
acteristic; TNF, tumor necrosis factor.
Calleja-Agius. Cytokines and threatenedmiscarriage.
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blood in the developing placenta in TM.
If the offspring is otherwise normal, ele-
vated TNF levels, in fact, might have a
protective effect to dampen the harm
that is caused by oxidative stress, thus al-
lowing the TM to proceed to a normal
outcome. IFN production by periph-
eral lymphocytes in very early pregnancy
is higher in normal women compared
with women with recurrent miscar-
riage.42 By contrast, IL-10 is known to be
an antiinflammatory cytokine,45 and as
hown in our study and others,46,47 high
evels of IL-10 are associated with suc-
essful outcome.
We also found that, when the ratios of
FIGURE 4
Receiver operator characteristics (
Tumor necrosis factor (TNF )-R2 was shown to b
nterval, 0.47-0.75). A cutoff level of 2202 pg/m
he prediction of miscarriage.
IFN, interferon; IL, interleukin.
alleja-Agius. Cytokines and threatenedmiscarriage. Am J Oh1/Th2 cytokines were calculated,here was a shift towards Th1 cytokines
ith elevated TNF/IL-10 and IFN/
IL-10 ratios in patients with TM who
subsequently miscarried. This suggests
that, if there is a rise in proinflammatory
cytokines in womenwith TM, there is an
even bigger rise in the antiinflammatory
cytokines to counteract the harmful ef-
fect of proinflammatory cytokines such
as TNF and IFN. TNF/IL-10 and
FN/IL-10 ratios are more representa-
tive of the Th1/Th2 balance, rather than
the absolute individual cytokine levels. If
there is an overall imbalance with a pre-
dominance of Th1 cytokines, then TM
ends up in miscarriage. This pattern is
comparable with that found in women
C ) curves for each cytokine and rece
e biomarker that best predicts miscarriage, with
f TNF-R2 gave a sensitivity of 63%, a specificity
t Gynecol 2011.with recurrent miscarriages; the Th1/
JULY 2011 AmericTh2 cytokine balance ofwomenwithTM
who proceed to normal pregnancy out-
come is similar towomenwith successful
pregnancy outcome.48-55
Our data also show that the TNF/
IL-6 ratio, but not the IFN/IL-6 ratio,
was also significantly higher in women
with subsequent miscarriage. This could
be explained by the fact that IL-6 has
both pro- and antiinflammatory proper-
ties. The classification of IL-6 as a Th1-
type cytokine in studies on preterm la-
bor56,57 or as a Th2 type cytokine in early
regnancy58-61 remains controversial.
Recently, it has been demonstrated that
IL-6 is involved in the promotion of Th2
differentiation and the inhibition of Th1
or
area under the curve of 0.65 (95% confidence
62%, and a positive predictive value of 44% forRO pt
e th an
L o of
bstepolarization.62 During the first trimes-
an Journal of Obstetrics& Gynecology 83.e13
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Research Basic Science: Obstetrics www.AJOG.orgter, IL-6 contributes to tissue remodeling
that is associated with placentation, the
hematopoiesis function of the secondary
yolk sac, and the generation of new
vessels in placental villi.36 One possible
mechanism of IL-6 in preventing mis-
carriage is modulation of the quality of
the Th2 response by increasing the pro-
portion of blocking asymmetric anti-
bodies during implantation and placen-
tal vascularization.62
Although the sensitivity and specificity
of the cytokines/receptors in our study
are not accurate enough for treatment
decisions, a combinationof cytokines to-
gether with other biomarkers in the fu-
ture may prove to be useful clinically.
Previous studies have shown that TNF-
receptors are useful in first-trimester
screening of women who are at subse-
quent risk of preeclampsia.63,64 By con-
rast, elevated levels of TNF-R1 and
NF-R2 have been described as markers
f normal human pregnancy, although a
ack of soluble TNF-receptors have been
ssociatedwith spontaneousmiscarriage
FIGURE 5
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There is a significantly higher tumor necrosis fac
stimulation in patients with threatened miscarriag
IFN, interferon; IL, interleukin; pg/mL, picograms per milliliter.
alleja-Agius. Cytokines and threatenedmiscarriage. Am J On women who undergo recurrent mis-
83.e14 American Journal of Obstetrics& Gynecoloarriage.65 In our study, there was signif-
icantly higher TNF-R1 levels in the
plasma of patients with TM who had a
normal pregnancy. Circulating TNF-re-
ceptor levels reflect TNF activity; thus,
levated plasma levels of TNF can be
explained by increased levels of TNF-
receptors.
The novelty of this study is that blood
sampling has been carried out in patients
with TM at the time of presentation with
a viable fetus who then were followed
prospectively. Most other studies in-
clude women who had already miscar-
ried.66-68 In contrast to what previous
investigators have carried out, where
experiments were done on cultured pe-
ripheral blood mononuclear cells,69,70
fluorescent antibody-labeled whole blood
was analyzed by flow cytometry in this
case. In view of the patient groups that
were recruited (pregnant women who
were experiencing vaginal bleeding in
the first trimester), we aimed to sample
smaller volumes of blood (1 mL) for the
entire experiment (100 L/cytokine or
d
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TM ) with normal pregnancy outcome (P .05).
t Gynecol 2011.receptor), compared with aminimumof m
gy JULY 201150 mL in the peripheral blood mononu-
clear cell culture experiments. Also,
whole blood analysis with incubation, as
carried out in our study, with the use of a
water bath at 37°C in atmospheric con-
ditions, rather than in a CO2 incubator,
imics physiologic conditions and re-
ects the in vivo scenario, compared
ith experiments on isolated peripheral
lood mononuclear cells. This method
as been used successfully by other
roups as well.71-73
The limitation of this study was that
inevitably there were fewer women who
were recruited whose threatened preg-
nancy ended up in miscarriage, espe-
cially in the flow cytometry subgroup.
Epidemiologic studies have shown that
the miscarriage rate in women with TM
is up to 14%.74 The other drawback of
his study was that we did not have data
n the karyotype of the products of con-
eption of the patients who eventually
iscarried. The reason for this is that
ost patients either had a completemis-
arriage or were treated expectantly;
herefore, it was not possible to carry out
aryotyping. The reason that karyotyp-
ng would have been useful is that it is
nown that up to 50% of miscarriages
ccur because of a chromosomal abnor-
FIGURE 6
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in monocytes at basal
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TNFR1 TNFR2
0
10
20
30
40
TM - Normal Pregnancy Outcome
TM - Miscarriage
Type of TNF receptors
R
ec
ep
to
rs
 in
 p
g
/m
L
There were no significant differences between
threatened miscarriage (TM ) with normal preg-
nancy outcome and miscarriage.
pg/mL, picograms per milliliter; TNF, tumor necrosis factor.
Calleja-Agius. Cytokines and threatenedmiscarriage. Am J
Obstet Gynecol 2011.loo
tor
e (
bsteality.75,76 Also, it has been shown that
t
d
s
m
www.AJOG.org Basic Science: Obstetrics Researchpatientswith a history ofmiscarriage and
decreased circulating levels of TNF had
a significantly higher chance of having a
subsequent miscarriage with normal
karyotype.77
The immune response towards ele-
vated Th1 cytokines that has been dem-
onstrated in our study in patients with
TM who subsequently miscarry is simi-
lar to that described in preterm delivery.
The onset of preterm labor is associated
with increased proinflammatory cyto-
kines such as TNF.78 Progesterone
reatment reduces the rates of preterm
elivery in singleton pregnancies with
hort cervical length79 and in women
with a history of preterm birth80 by pre-
ventingTNF-induced apoptosis of fetal
embranes.81,82 Future clinical trials
and in vitro studies should be carried out
to confirm the effect of progesterone in
reversing the imbalance of Th1/Th2 in
women with TM. f
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